Short-course antiretroviral therapy in primary HIV infection.

ABSTRACT:

Background

Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus (HIV) infection may delay disease progression but has not been adequately evaluated.

Methods

We randomly assigned adults with primary HIV infection to ART for 48 weeks, ART for 12 weeks, or no ART (standard of care), with treatment initiated within 6 months after seroconversion. The primary end point was a CD4+ count of less than 350 cells per cubic millimeter or long-term ART initiation.

Results

A total of 366 participants (60% men) underwent randomization to 48-week ART (123 participants), 12-week ART (120), or standard care (123), with an average follow-up of 4.2 years. The primary end point was reached in 50% of the 48-week ART group, as compared with 61% in each of the 12

SUBMITTER: SPARTAC Trial Investigators 

PROVIDER: S-EPMC4131004 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature